CD4+ T-cell-guided structured treatment interruptions of antiretroviral therapy in HIV disease: Projecting beyond clinical trials

Antiviral Therapy

Volumn 15, Issue 3, 2010, Pages 351-361

  Yazdanpanah, Yazdan ^a,b   Wolf, Lindsey L ^c   Anglaret, Xavier ^d,e   Gabillard, Delphine ^d   Walensky, Rochelle P ^c,f,g   Moh, Raoul ^e   Danel, Christine ^e   Sloan, Caroline E ^c   Losina, Elena ^c,f,g,h   Freedberg, Kenneth A ^c,f,h  

^a CENTRE HOSPITALIER DE TOURCOING   (France)

^b UNIV LILLE   (France)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d INSERM   (France)

^e Programme PAC CI   (Côte d’Ivoire)

^f HARVARD MEDICAL SCHOOL   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; AFRICA; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; COHORT ANALYSIS; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EXPECTANCY; MALE; PRIORITY JOURNAL; RISK REDUCTION; SIMULATION; TREATMENT OUTCOME; VIRUS RESISTANCE; CD4 LYMPHOCYTE COUNT; COMPUTER SIMULATION; COTE D'IVOIRE; DRUG ADMINISTRATION; DRUG EFFECTS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; VIROLOGY;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; COMPUTER SIMULATION; COTE D'IVOIRE; DRUG ADMINISTRATION SCHEDULE; HIV INFECTIONS; HIV-1; HUMANS; LIFE EXPECTANCY; TREATMENT OUTCOME;

EID: 77952917075     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1542     Document Type: Article

References (46)

1. Palella FJ, Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-860. (Pubitemid 28135961)
2. Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Federation National des Centres de Lutte contre le SIDA. AIDS 1997; 11:F101-F105.
3. + count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296.
4. Danel C, Moh R, Minga A, et al. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet 2006; 367:1981-1989.
5. DART Trial Team. Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts <200 cells/microl. AIDS 2008; 22:237-247.
6. Anglaret X, Messou E, Ouassa T, et al. Pattern of bacterial diseases in a cohort of HIV-1 infected adults receiving cotrimoxazole prophylaxis in Abidjan, Cote d'Ivoire. AIDS 2003; 17:575-584. (Pubitemid 36293111)
7. Minga A, Danel C, Abo Y, et al. Progression to WHO criteria for antiretroviral therapy in a 7-year cohort of adult HIV-1 seroconverters in Abidjan, Cote d'Ivoire. Bull World Health Organ 2007; 85:116-123. (Pubitemid 46203941)
8. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 2008; 197:1133-1144.
9. + Cell counts and HIV RNA levels during follow-up. J Infect Dis 2008; 197:1145-1155.
10. Cooper DA, Emery S, Cordery DV. Disease progression and fatal outcomes in HIV-infected patients during interruption of antiretroviral treatment. J Infect Dis 2008; 197:775. [Author reply 775-776].
11. Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 2001; 344:824-831. (Pubitemid 32222162)
12. Goldie SJ, Yazdanpanah Y, Losina E, et al. Cost-effectiveness of HIV treatment in resource-poor settings-the case of Cote d'Ivoire. N Engl J Med 2006; 355:1141-1153. (Pubitemid 44394920)
13. Paltiel AD, Weinstein MC, Kimmel AD, et al. Expanded screening for HIV in the United States - an analysis of cost-effectiveness. N Engl J Med 2005; 352:586-595.
14. Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis 2006; 194:11-19. (Pubitemid 43911920)
15. Yazdanpanah Y, Losina E, Anglaret X, et al. Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Cote d'Ivoire: a trial-based analysis. AIDS 2005; 19:1299-1308. (Pubitemid 41224899)
16. Gold MR, Siegel JE, Russell LB, Weinstein MC (Editors). Cost Effectiveness in Health and Medicine. New York: Oxford University Press 1996.
17. Danel C, Moh R, Anzian A, et al. Tolerance and acceptability of an efavirenz-based regimen in 740 adults (predominantly women) in West Africa. J Acquir Immune Defic Syndr 2006; 42:29-35. (Pubitemid 43947943)
18. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 revision. (Updated 7 August 2006. Accessed 8 January 2009.) Available from http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf
19. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946-954.
20. Danel C, Moh R, Chaix ML, et al. Two-months-off, four-months-on antiretroviral regimen increases the risk of resistance, compared with continuous therapy: a randomized trial involving West African Adults. J Infect Dis 2009; 199:66-76.
21. Messou E, Chaix ML, Gabillard D, et al. Strong association between medication possession ratio and early virological outcomes in adults on ART in Côte d'Ivoire. 17th Conference on Retroviruses and Opportunistic Infections. 16-19 February 2010, San Francisco, CA, USA. Abstract 587.
22. Losina E, Yazdanpanah Y, Deuffic-Burban S, et al. The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in Côte d'Ivoire. Antivir Ther 2007; 12:543-551. (Pubitemid 47041153)
23. Cole SR, Hernan MA, Robins JM, et al. Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol 2003; 158:687-694.
24. Silverberg MJ, Neuhaus J, Bower M, et al. Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS 2007; 21:1957-1963. (Pubitemid 47329772)
25. + cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis 2007; 44:441-446.
26. Le Moing V, Thiebaut R, Chene G, et al. Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/ml during treatment with antiretroviral drugs. HIV Med 2007; 8:156-163.
27. Wester CW, Okezie OA, Thomas AM, et al. Higher-than-expected rates of lactic acidosis among highly active antiretroviral therapy-treated women in Botswana: preliminary results from a large randomized clinical trial. J Acquir Immune Defic Syndr 2007; 46:318-322.
28. Bolhaar MG, Karstaedt AS. A high incidence of lactic acidosis and symptomatic hyperlactatemia in women receiving highly active antiretroviral therapy in Soweto, South Africa. Clin Infect Dis 2007; 45:254-260.
29. Ananworanich J, Gayet-Ageron A, Le Braz M, et al. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet 2006; 368:459-465.
30. Maggiolo F, Ripamonti D, Gregis G, Quinzan G, Callegaro A, Suter F. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trial. AIDS 2004; 18:439-446. (Pubitemid 38365871)
31. Ruiz L, Paredes R, Gomez G, et al. Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients. AIDS 2007; 21:169-178.
32. 3: 48-week Treatment Interruption in Early Starters Netherlands Study (TRIESTAN). J Acquir Immune Defic Syndr 2007; 44:395-400.
33. Skiest DJ, Su Z, Havlir DV, et al. Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170. J Infect Dis 2007; 195:1426-1436.
34. Phillips AN, Carr A, Neuhaus J, et al. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther 2008; 13:177-187.
35. Maggiolo F, Airoldi M, Callegaro A, et al. CD4 cell-guided scheduled treatment interruptions in HIV-infected patients with sustained immunologic response to HAART. AIDS 2009; 23:799-807.
36. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191-201. (Pubitemid 38917996)
37. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354:251-260.
38. Hammer SM, Eron JJ, Jr., Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555-570.
39. Gilks CF, Crowley S, Ekpini R, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 2006; 368:505-510. (Pubitemid 44142772)
40. Mackie NE, Fidler S, Tamm N, et al. Clinical implications of stopping nevirapine-based antiretroviral therapy: relative pharmacokinetics and avoidance of drug resistance. HIV Med 2004; 5:180-184. (Pubitemid 38765286)
41. Schweighardt B, Ortiz GM, Grant RM, et al. Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions. AIDS 2002; 16:2342-2344. (Pubitemid 35449024)
42. Arnedo-Valero M, Garcia F, Gil C, et al. Risk of selecting de novo drug-resistance mutations during structured treatment interruptions in patients with chronic HIV infection. Clin Infect Dis 2005; 41:883-890.
43. Taylor S, Boffito M, Khoo S, Smit E, Back D. Stopping antiretroviral therapy. AIDS 2007; 21:1673-1682.
44. Fox Z, Phillips A, Cohen C, et al. Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen. AIDS 2008; 22:2279-2289.
45. Médecins Sans Frontières. Untangling the web of price reductions. 11th edition. 2008. (Updated July 2008. Accessed 8 January 2009.) Available from http://www.msfaccess.org/fileadmin/user-upload/diseases/hiv-aids/ Untangling-the-Web/Untanglingtheweb-July2008-English.pdf
46. French National Agency for Research on AIDS and Viral Hepatitis. Early antiretroviral treatment and/or early isoniazid prophylaxis against tuberculosis in HIV-infected adults (ANRS 12136 TEMPRANO). (Updated 23 September 2009. Accessed 9 November 2009.) Available from http://clinicaltrials.gov/ct2/show/ NCT00495651?term=temprano&rank=1